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Stenting Versus Endarterectomy for Restenosis Following Prior
Ipsilateral Carotid Endarterectomy
An Individual Patient Data Meta-analysis
Margriet Fokkema, MD,∗† Joyce E. P. Vrijenhoek, MD,∗‡§ Hester M. Den Ruijter, PhD,‡¶
Rolf H. H. Groenwold, MD, PhD,¶ Marc L. Schermerhorn, MD,† Michiel L. Bots, MD, PhD,¶
Gerard Pasterkamp, MD, PhD,‡ Frans L. Moll, MD, PhD,∗ and Gert Jan De Borst, MD, PhD∗; on behalf of the
TREAT CARE Study Group
Objective: To study perioperative results and restenosis during follow-up
of carotid artery stenting (CAS) versus carotid endarterectomy (CEA) for
restenosis after prior ipsilateral CEA in an individual patient data (IPD) meta-
analysis.
Background: The optimal treatment strategy for patients with restenosis after
CEA remains unknown.
Methods: A comprehensive search of electronic databases (Medline, Embase)
until July 1, 2013, was performed, supplemented by a review of references.
Studies were considered for inclusion if they reported procedural outcome of
CAS or CEA after prior ipsilateral CEA of a minimum of 5 patients. IPD
were combined into 1 data set and an IPD meta-analysis was performed.
The primary endpoint was perioperative stroke or death and the secondary
endpoint was restenosis greater than 50% during follow-up, comparing CAS
and CEA.
Results: In total, 13 studies were included, contributing to 1132 unique pa-
tients treated by CAS (10 studies, n = 653) or CEA (7 studies; n = 479).
Among CAS and CEA patients, 30% versus 40% were symptomatic, re-
spectively (P < 0.01). After adjusting for potential confounders, the primary
endpoint did not differ between CAS and CEA groups (2.3% vs 2.7%, ad-
justed odds ratio 0.8, 95% confidence interval (CI): 0.4–1.8). Also, the risk of
restenosis during a median follow-up of 13 months was similar for both groups
(hazard ratio 1.4, 95% (CI): 0.9–2.2). Cranial nerve injury (CNI) was 5.5%
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in the CEA group, while CAS was in 5% associated with other procedural
related complications.
Conclusions: In patients with restenosis after CEA, CAS and CEA showed
similar low rates of stroke, death, and restenosis at short-term follow-up. Still,
the risk of CNI and other procedure-related complications should be taken
into account.
(Ann Surg 2014;00:1–7)
R estenosis after carotid endarterectomy (CEA) hampers the long-term durability of CEA in terms of stroke-free survival.1,2 The
reported incidence of restenosis is variable according to its defini-
tion, method of measurement, and duration of follow-up. The rate
of restenosis at 2 years has varied from 6% to 14% using duplex
ultrasound with more than 50% restenosis as criterion.3,4 Restenotic
lesions have been shown to be clinically important, because recurrent
lesions with more than 70% stenosis have been related to an increased
risk for ipsilateral stroke.5 However, the optimal treatment strategy
of significant restenotic lesions remains unclear.6–8 Redo-CEA po-
tentially leads to a more challenging procedure,9,10 and therefore
restenosis following prior CEA has been adapted among the “high-
risk” criteria within several registries and clinical trials comparing
outcome after carotid artery stenting (CAS) versus CEA.11,12 CAS
has been suggested and applied as an alternative for CEA in these
deemed high-risk cases.13 However, there is no evidence suggesting
that the (peri)procedural risk for stroke in these patients is lower for
CAS when compared with CEA. Although the Stenting and Angio-
plasty with Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) trial is the only randomized controlled trial comparing
CAS versus CEA that included a subgroup of patients with restenosis
after prior ipsilateral CEA, no subgroup analysis was performed in
these patients.11 Numerous single centers and several larger registries
have reported on outcome of patients treated for restenosis after prior
ipsilateral CEA through CAS or CEA,14–16 but only few (nonrandom-
ized) studies reported on outcome of both treatment modalities.16–22
Generally, small number of patients in each registry limits the cur-
rent evidence on the most desirable treatment strategy for restenosis.
Most studies were underpowered to stratify patients in different risk
categories (ie, based on symptoms). In addition, confounding by in-
dication is a severe threat for these registries when evaluating both
treatment modalities and not adjusting for potential confounders such
as cardiovascular risk factors. While a randomized control trial is be-
yond perspective, accurate outcome analysis with the use of individual
patient data (IPD) seems the highest retrievable level of evidence at
present.
Therefore, we pooled all the publically available evidence re-
garding surgical and endovascular treatment of patients with resteno-
sis after prior CEA into a dataset with IPD, and compared outcome
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after CAS and CEA. We hypothesized that CAS is not superior to
CEA regarding perioperative results and outcome during follow-up.
METHODS
The study protocol defining the process for obtaining patient
level data and the preplanned analyses was designed by the core study
group (M.F., J.V., H.R., F.M., G.J.B.) and approved by all collaborat-
ing authors of the TREAT CARE (optimal TREATment of CArotid
REstenosis) study group. The guidelines for meta-analyses of obser-
vational studies were followed.23
Search Strategy and Study Selection
A systematic search was performed on PubMed and Embase
databases until July 1, 2013. Synonyms for “recurrent carotid steno-
sis” and “carotid endarterectomy” and/or “carotid angioplasty and
stenting” were used to identify relevant studies. No filters or restric-
tions were applied (see Table 1 for search query). References of
relevant articles were screened for additional relevant studies. Two
independent researchers (M.F. and J.V.) screened all publications on
predefined inclusion criteria: (1) patients who underwent CEA or
CAS for restenosis after prior ipsilateral CEA; (2) data on the pri-
mary endpoint reported; (3) publications in English, Dutch, German,
French, or Spanish; and (4) original data. Studies were excluded if
there was no full-text version available or if the number of patients
treated was less than 5. Duplicates were removed manually. All cita-
tions that met the inclusion criteria were thoroughly assessed for final
inclusion.
Our search resulted in 1334 articles on PubMed and 1207 on
Embase. After removing duplicates, 1521 articles remained, of which
1428 were excluded after screening citations. Of the remaining 93
articles, another 14 were excluded because they did not meet the
inclusion criteria. Reference check of these 93 articles yielded 5
relevant studies. This resulted in a final number of 84 eligible articles
(Fig. 1).
Individual Patient Data Acquisition
Authors of eligible articles were contacted per e-mail or per
post with a request to join the TREAT CARE initiative. We obtained
the contact details of any author listed on the article (sequence of
contact: corresponding author, first author, senior author, other coau-
thors). If we did not receive a response after 1 week, the authors were
contacted again, with a maximum of 4 attempts within a timeframe
of 3 months. From the 84 eligible articles (7609 patients, possibly in-
cluding duplicate patients and interventions others than CEA/CAS),
we received IPD from 13 studies.15,16,18,19,24–32 From the remaining
71 studies, IPD could not be retrieved because 30 authors did not
respond, 26 did respond but the data were not available [no access
to the data anymore without a clear reason why (13); no access to
the data anymore because of change of institution, retirement, or
institutional/study group restrictions (7); data destroyed or lost (4);
data not digital (2)]. Three studies replied, but only provided sum-
mary data, and 11 study groups responded that they were not willing
TABLE 1. Search Strategy
Recurrent stenosis OR Recurrent carotid stenosis OR Restenosis OR
Post-CEA stenosis OR Post carotid endarterectomy stenosis OR Post
endarterectomy stenosis
AND
CEA OR carotid endarterectomy OR carotid surgery OR Carotid
revascularization OR OCS OR Open surgical repair OR Redo surgery
OR Endarterectomy OR CAS OR Carotid artery stenting OR Carotid
angioplasty OR Carotid stenting
to participate (unknown reasons). One study cohort33 was not con-
tacted because the cohort was a duplicate of another study.29 Of the
studies that provided IPD, patients treated with interposition grafting
(n = 43), carotid bypass (n = 24), or angioplasty only (n = 2) were
excluded from the database. Furthermore, 32 bilateral or tertiary pro-
cedures were excluded, resulting in a total of 1132 unique patients
(479 CEA, 653 CAS) (Fig. 1 and Table 2).
Data Extraction and Outcome
Demographics, patient-related risk factors, procedural details,
perioperative outcome, and follow-up data were extracted from the
received IPD files and aggregated into 1 database after careful data
examination. The primary endpoint of the current study was any
perioperative stroke or death (a 30-day postoperative timeframe for
all studies except for 1 (a 1-week timeframe). A combined endpoint
was chosen because of the low event rate, and the inherent inability to
compare treatments with enough power. Use of a combined endpoint
is limited by difficulties in interpretation (ie, potentially opposite
treatment effects of separate endpoints) and differences in importance
to patients. More important events such as death are often associated
with lower event rates and smaller treatment effects, which can be
misleading. To partly overcome this limitation, we have also analyzed
the individual endpoints (stroke and death) separately.
The secondary endpoint was recurrent carotid restenosis
(>50%) during follow-up. Other procedural complications such as
cranial nerve injury (CNI), neck hematoma, wound infection, brady-
cardia/arrhythmia during the procedure, residual stenosis (>30%),
technical failure, and access site complications were also examined.
Statistical Analysis
Baseline characteristics between CEA and CAS patients were
compared using the Fisher exact test for categorical variables, and
parametric (Student t test) or nonparametric test (Mann-Whitney U
test) for continuous variables.
The primary endpoint (any perioperative stroke or death) was
compared between CEA and CAS with the Fisher exact test. For ad-
justed analyses, potential confounders were previously determined on
the basis of availability (<75% missing values) and clinical relevance
by 4 members of the core study group (M.F., J.V., H.R., and G.B.). To
prevent confounding by indication and improve the reliability of our
results, factors that were assumed to influence outcome, but also treat-
ment decisions (and thus bias estimates of treatment effects), were
chosen. These variables were age, gender, smoking, hypertension,
degree of ipsilateral stenosis, symptom status, diabetes, and coro-
nary artery disease. To prevent bias due to exclusion of observations
because of missing values in these variables, single imputation was
used (using the multivariate imputation by chained equations algo-
rithm in R with 1 imputation).34,35 Predictors in the imputation model
included all variables to be imputed, including the primary endpoint,
as recommended previously.26 Because of low power in this analy-
sis due to the low event rate of stroke or death, a propensity score
including the previously listed variables was constructed. In short,
the propensity score is a method to control for confounding and is
derived from a logistic regression model to estimate the probability
of being exposed to a certain treatment. Hence, patients with the
same score will on average be balanced in confounder characteristics
and comparing subjects with the same score will not be confounded
by these characteristics.36 With our score, we obtained considerable
balance between treatment groups. The primary endpoint compar-
ing CEA and CAS was subsequently analyzed by logistic regression
model (events were recorded mostly in a 30-day postoperative time-
frame), adjusted for the propensity score. Odds ratios (ORs) and 95%
confidence intervals (CIs) are reported.
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FIGURE 1. Flow diagram of TREAT CARE study.
TABLE 2. Overview of Included Studies
Article Type of Study Years of Inclusion CEA (N) CAS (N)
Alric et al24 Single center 1997–2000 0 15
Attigah et al19 Single center 1989–2007 28 41
Benitez et al25 Single center 1996–1997 0 5
Bettendorf et al18 Single center 1998–2006 28 29
Domenig et al15 Single center 1990–2001 82 0
Dorigo et al26 Single center 2005–2011 37 58
Eskandari et al27 Single center 2001–2009 0 70
Fokkema et al16 Multicenter 2003–2012 212 220
Halabi et al28 Single center 1998–2004 0 72
Jain et al29 Single center 1988–2005 80 0
Kadkhodayan et al30 Single center 1996–2005 0 73
Radak et al31 Multicenter (2 centers) 2000–2008 12 0
Vos et al32 Single center 1997–2006 0 70
Total 479 653
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The secondary endpoint (restenosis during follow-up) was an-
alyzed using a multivariable Cox proportional hazard model to allow
time to event analyses, adjusted for the same propensity score as
mentioned earlier. Hazard ratios (HRs) and 95% CIs are reported.
SPSS version 20.0 (IBM Corp, IBM SPSS Statistics for Win-
dows, Armonk, NY) and R Statistical software37 were used for statis-
tical analyses (R packages “mice” and “survival”). P’s < 0.05 were
considered significant in all statistical analyses.
RESULTS
Baseline Characteristics
Baseline characteristics of patients undergoing CEA (n = 479)
and CAS (n = 653) for restenosis after prior ipsilateral CEA are
shown in Table 3. Although CAS patients were more likely to be older
(mean age 70 vs 68 years, P < 0.01), CEA patients were more often
symptomatic (40% vs 30%, P < 0.01). Severe ipsilateral stenosis
greater than 70% was also found more frequently compared with
CAS patients (94% vs 85%, P < 0.01). Data on time to restenosis
from the initial CEA were available for 56% (n = 639) of patients.
Median time from primary CEA to reintervention was significantly
shorter for CAS when compared with CEA patients (14 vs 52 months,
P < 0.01). Time to reintervention was also shorter for asymptomatic
versus symptomatic patients (18 vs 33 months, P < 0.01). Of these
639 patients, 55% of patients (80% CAS and 20% CEA) had early
restenosis (<24 months after primary CEA). Inclusion periods for
CAS and CEA were similar, as shown in Table 4. Specifically, median
year of start of inclusion was 1997.5 for CAS and 1998 for CEA.
Primary Endpoint
Perioperative stroke or death rate did not differ between CAS
and CEA (2.3% vs 2.7%, OR = 0.8, 95% CI: 0.4–1.8). After propen-
sity score adjustment, no difference was observed in the direction and
significance of this endpoint (adjusted OR = 0.8, 95% CI: 0.4–1.8).
In addition, no differences in adjusted ORs for myocardial
infarction, any stroke, and mortality were found between the 2 treat-
ment modalities (Table 5). Similarly, no differences in stroke or death
rate were identified between symptomatic and asymptomatic patients
(3.4% vs 2.0%, P = 0.15). Comparing CAS and CEA also showed
no significant differences between symptomatic (3.1% vs 3.7%, ad-
justed OR = 0.8, 95% CI: 0.3–2.6) and asymptomatic patients (2.0%
vs 2.1%, adjusted OR = 0.8, 95% CI: 0.3–2.3). Although patients
treated for early restenosis tended to have lower stroke or death rates
with CAS than with CEA (1.1% vs 2.9%, adjusted OR = 0.3, 95% CI:
0.04–1.8), the difference did not reach statistical significance. Among
all patients with late restenosis, stroke or death rate after CAS was
2.6% and after CEA was 2.2% (adjusted OR = 1.6, 95% CI: 0.3–7.8).
Secondary Endpoint
Data on restenosis during follow-up was available for 712 (400
CAS, 312 CEA) patients from 10 studies,14,16,18,19,24,26,28–31 with a
median follow-up time of 13 months (interquartile range: 8.7–26). In
the CAS group, restenosis greater than 50% occurred in 34 patients
(8.5%), and in 16 patients (4.0%) when using 70% as cutoff. For CEA
patients, these numbers were 23 (7.3%) and 24 (7.7%), respectively,
and there were 5 occlusions. In the adjusted analysis, no statistically
significant difference was found regarding restenosis greater than
50% or 70% (including occlusions) between CAS and CEA patients
(>50%: adjusted HR = 1.4, 95% CI: 0.7–2.2 and>70%: adjusted HR
= 0.7, 95% CI: 0.4–1.4). Adjusted restenosis risk with a 50% cutoff
was similar for both symptomatic (HR = 1.8, 95% CI: 0.8–3.7) and
asymptomatic patients (HR = 1.3, 95% CI: 0.8–2.2).
Regarding clinical outcome during follow-up, there were 7
strokes (1 in the CAS group and 6 in the CEA group) and 7
cardiovascular-related deaths (2 in the CAS group and 5 in the CEA
group) during 453 person years of follow-up in CAS patients and 731
person years of follow-up in CEA patients. These limited numbers
did not allow for a reliable comparison between the treatment groups
or for multivariable analysis.
Other Complications
After CAS, technical failure rate was 1.3%, residual stenosis
was seen in 0.3%, access site complications in 1.9%, and bradycardia
or arrhythmia during the procedure occurred in 1.4% of cases. After
CEA, CNI was identified in 5.5% (N = 26) of patients, bleeding in
2.7% (N = 13), and wound infections in 0.2% (N = 1). From the 26
TABLE 3. Baseline Characteristics
CEA (n = 479) CAS (n = 653)
N/Total % N/Total % P
Age, mean ± SD, yr 67.8 ± 9.3 69.7 ± 8.7 .001
Gender (male) 238/479 49.7 345/653 52.8 0.31
Time to reintervention, median (IQR), mo 52 (77) 14 (39) <.001
Patch (vs primary) closure during primary CEA 30/37 81.1 68/87 78.2 0.81
Side (right) 182/399 45.6 241/504 47.8 0.55
Symptomatic 189/479 39.5 193/653 29.6 .001
Degree of ipsilateral stenosis <.001
50%–69% 30/459 6.5 86/589 14.6
>70% 429/459 93.5 503/589 85.4
Hypertension 400/479 83.5 504/573 88.0 0.041
Diabetes mellitus 147/479 30.7 175/570 30.7 1.0
Coronary artery disease 201/479 42.0 220/592 37.2 0.12
Renal failure 18/295 6.1 45/428 10.5 0.044
Hypercholesterolemia 170/209 81.3 209/341 61.3 0.067
Smoking (prior or current) 388/468 82.9 332/570 58.2 <0.001
Antiplatelet therapy 354/414 85.5 444/457 97.2 <0.001
Statin use 270/360 75.0 284/364 78.0 0.38
Contralateral occlusion 30/318 9.4 58/566 10.2 0.73
The bold values indicate statistical significance.
IQR indicates interquartile range.
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TABLE 4. Perioperative Stroke and Death Rate of 13 Included Studies
CEA, N (%) 95% CI CAS, N (%) 95% CI
Alric et al24 NA NA 0/15 (0) 0%–25%
Attigah et al19 2/28 (7.1) 0%–25% 0/41 (0) 0%–11%
Benitez et al∗25 NA NA 0/5 (0) 0%–54%
Bettendorf et al18 1/28 (3.6) 0%–20% 1/29 (3.4) 0%–20%
Domenig et al15 2/82 (2.4) 0%–9.4% NA NA
Dorigo et al26 0/37 (0) 0%–12% 0/58 (0) 0%–7.8%
Eskandari et al27 NA NA 1/70 (1.4) 0%–8.7%
Fokkema et al16 7/212 (3.3) 1.5%–7.0% 7/220 (3.2) 1.4%–6.7%
Halabi et al28 NA NA 2/72 (2.8) 0%–11%
Jain et al29 1/80 (1.2) 0%–7.8% NA NA
Kadkhodayan et al30 NA NA 4/73 (5.5) 1.8%–14%
Radak et al31 0/12 (0) 0%–30% NA NA
Vos et al∗32 NA NA 0/70 (0) 0%–6.5%
All percentages are stroke and death rate adapted from individual patient data. All rates are 30-day postoperative event rate, unless indicated otherwise.
∗7-day postoperative event rate.
NA indicates not applicable.
TABLE 5. Perioperative Outcome in All Patients Undergoing CEA or CAS
CEA, N/Total % (95% CI) CAS, N /Total % (95% CI) Adjusted OR (95% CI)
Primary outcome
Any stroke or death 13/479 2.7 (1.5–4.7) 15/653 2.3 (1.3–3.9) 0.8 (0.4–1.8)
Any stroke 12/479 2.5 (1.4–4.5) 13/653 2.0 (1.1–3.5) 0.8 (0.4–1.8)
Death 3/479 0.6 (0.2–2.0) 4/653 0.6 (0–1.2) 0.9 (0.2–4.4)
Myocardial infarction 7/400 1.8 (0.8–3.7) 8/653 1.2 (0.6–2.5) 0.7 (0.2–1.9)
Other complications
Cranial nerve injury 26/474 5.5 (3.7–8.0) 1/126 0.8 (0–5.0) NA∗
Bleeding 13/474 2.7 (1.5–4.7) 1/72 1.4 (0–8.5) NA∗
Wound infections 1/462 0.2 (0–1.4) NA NA NA
Technical failure NA NA 8/640 1.3 (0.6–2.6) NA
Residual stenosis NA NA 2/640 0.3 (0–1.3) NA
Access site complication NA NA 11/580 1.9 (1.0–3.5) NA
Bradycardia/arrhythmia during procedure NA NA 6/441 1.4 (0.6–3.1) NA
ORs for CAS compared to CEA are shown and are adjusted for a propensity score including age, gender, smoking, hypertension, degree of stenosis, symptom status,
diabetes, and coronary artery disease.
∗No statistical comparison done because of many missing cases in the CAS group.
NA indicates not applicable.
CNIs, information on reversibility was available for 23 patients. The
majority of lesions were transient (N = 22), and 1 persistent CNI was
reported.29 One transient CNI occurred in the CAS group; however,
this endpoint was only recorded in 2 studies.26,27
Sensitivity Analysis
Event rates of the included studies varied from 0% to 5.5%
for CAS and 0% to 7.1% for CEA (Table 4). Sensitivity analysis
was performed by excluding patients from the largest study.16 In
this subset analysis, a similar effect size and direction was identified
for both primary and secondary endpoints compared with the entire
cohort of 1132 patients (stroke or death, OR = 1.0, 95% CI: 0.3–3.1
and restenosis, HR = 1.1, 95% CI: 0.6–2.0). In addition, outcome
in the 4 studies with both treatments were analyzed separately to
differentiate treatment effect and study effects. This led to similar
results (OR for primary endpoint = 0.65, 95% CI: 0.26–1.7).
DISCUSSION
This meta-analysis of individual patients data from 13 studies
showed that in symptomatic and asymptomatic patients with resteno-
sis after prior ipsilateral CEA, CAS was not superior to CEA re-
garding perioperative stroke and death rate and restenosis rate during
follow-up. These results indicate that this criterion should not be used
to preferentially treat restenosis with CAS. As a consequence, both
CAS and CEA seem suitable options to treat restenosis after prior ip-
silateral CEA. Although CEA may be counterbalanced by a 5.5% risk
for CNI, CAS is limited by other complications such as access site
complications and technical failure. Our results indicate that choice
of treatment should probably be based on patient characteristics that
may influence outcome after CAS or CEA, such as severe comor-
bidities, aortic arch anatomy, and poor anatomical accessibility such
as excessive subcutaneous fat and/or a short neck. Unfortunately,
these factors were not readily available in this IPD analysis, as was
physician experience.
The criteria that determine “high-risk” for CEA have been a
matter of debate for a long time.13,38 It remains unclear whether these
patients are considered at increased risk for stroke, death, or other
periprocedural complications after CEA. Consequently, patients were
excluded from the major carotid trials comparing CAS and CEA39,40
and the optimal treatment for these patients remains a matter of
debate.
We found that the durability of both procedures at follow-up
was comparable, regardless of symptom status at baseline. However,
the mean follow-up duration was only 13 months, and especially
for the post-CAS situation increasing restenosis rates have been
reported.14 As a consequence, with longer follow-up duration, the
restenosis rate after CAS might further increase whereas the resteno-
sis rate after CEA may be more subtle. Furthermore, the 50% cutoff
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point to determine restenosis after CAS is questionable. Stent stiffness
and tortuosity in CAS patients may lead to higher velocity patterns
and subsequent increased degree of reported stenosis.41,42 Therefore,
the rate of restenosis in CAS patients may be overestimated when
compared with CEA patients. A prior study reported an increased in-
cidence of restenosis greater than 50% in CAS compared with CEA,
whereas this difference was absent when looking at restenosis greater
than 80%.21 In the current study, however, severe restenosis greater
than 70% or 80% was not statistically analyzed, because most of the
received IPD only reported on restenosis greater than 50%. Besides
the possible apparent in-stent restenosis in CAS patients, patients
were followed for a median of 13 months in this study, possibly indi-
cating that some restenosis cases have represented residual stenosis,
instead of new, recurrent stenotic lesions. In a clinical perspective, it
is important to consider that restenosis is usually asymptomatic.43
Although an increased risk for CNI in patients undergoing
redo-CEA has been reported previously,10,21 our rate of 5.5% was
very comparable to the risk of nerve injury in primary CEA (4.7%–
8.6%).12,44,45 A recent report on CNI did also not identify redo-
CEA as a risk factor for CNI.46 Other factors (such as urgency and
reexploration) proved to be important predictors. Importantly, the
CREST (Carotid Revascularization and Stenting Trial) found that
CNI was not associated with a sustained impact on quality of life
at 1 year.47 This can be explained because most lesions seem to be
transient and completely resolving (permanent rates <1%).47,48 We
also found that the majority of lesions had a transient nature. However,
it should be reaffirmed that permanent CNI can be a serious and
invalidating complication limiting the benefit of carotid surgery in
preventing stroke. The risk of CNI should be taken into account at all
times when selecting optimal treatment for patients with restenosis
after prior CEA.
The strength of this study is that we were able to adjust for
various risk factors, which may have had a significant impact on
treatment decisions and outcome after carotid intervention to prevent
confounding by indication. Although in most comparative analyses
CAS patients generally have increased risk factors compared with
CEA patients,13 in this study we found that comorbidities between
CEA and CAS patients were quite similar. This was also indicated
by the finding that adjustment for risk factors did not substantially
change outcome and may be a possible explanation for the absence
of differences between symptomatic and asymptomatic patients; the
propensity score took into account multiple factors which seemed
to be balanced between the groups. We were also able to perform
stratified analyses for time elapse to restenosis. This is important,
because early restenosis might follow a different pathophysiology
pattern, possibly influencing outcome. Excellent results with CAS in
early restenosis can be explained by a more stable plaque in restenotic
lesions caused by intimal hyperplasia, compared with primary lesions
or late restenosis with atherosclerotic plaque.49,50
LIMITATIONS
Although the response rate on our IPD data request was accept-
able, we could not acquire data from all studies. This could potentially
lead to selection bias, because results from acquired studies could re-
port a more positive outcome than excluded studies. We cannot make
inferences regarding the possible influence of excluded data, because
analyzing aggregate data from these studies would be less reliable
than IPD.51 In a similar manner, publication bias and poor reporting
could be an issue, as positive results are more likely to be published,
leading to an underestimation of the “real” risks of treatment. This
could have affected our study through an imbalance of the number
of studies conducted on CEA and CAS groups. Also, secondary out-
comes such as CNI can have a heterogenic character by differences
in definitions across studies. For CNI, the rate is also influenced
by method of assessment (eg, otolaryngeal examinations vs clinical
assessment), which may influence outcome. Unfortunately, these as-
pects are inherent in meta-analyses. Another concern with IPD is that
certain studies may have a greater impact on outcome than others.
However, we addressed this issue by conducting a sensitivity analysis
by excluding the largest study,16 and results did not change. Finally,
we could not completely adjust for confounding due to clustering of
patients within studies so residual confounding may still be present.
Ideally, in IPD meta-analysis, this is taken into account by analyzing
the data using a random effects model. However, for a number of
studies included in our analysis, all patients in the particular studies
were treated with the same treatment modality. Consequently, our
analysis could not differentiate between study effects (ie, differences
between studies such as expertise) and the actual treatment effect.
Nonetheless, this seems the best available evidence to date
given that a randomized controlled trial in this small group of patients,
accompanied by low event rates after the intervention, would not be
feasible in an achievable period of time.
CONCLUSIONS
In patients with restenosis after previous ipsilateral CEA, CAS
does not seem to be superior to redo-CEA in terms of procedural
stroke and death and prevention of short-term restenosis. This sug-
gests that both CAS and CEA may be considered as a treatment
modality in patients with an indication for intervention for recurrent
stenosis, though the risk of CNI and other procedure-related compli-
cations should be taken into account.
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